SEK 0.32
(-0.63%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 14.01 Million SEK | -25.21% |
2022 | 18.74 Million SEK | -9.88% |
2021 | 20.79 Million SEK | -0.53% |
2020 | 20.9 Million SEK | 169.1% |
2019 | 7.76 Million SEK | 62.91% |
2018 | 4.76 Million SEK | -53.11% |
2017 | 10.17 Million SEK | 254.85% |
2016 | 2.86 Million SEK | -9.33% |
2015 | 3.16 Million SEK | 231.24% |
2014 | 954.29 Thousand SEK | -52.34% |
2013 | 2 Million SEK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 29.06 Million SEK | -2.43% |
2024 Q1 | 29.78 Million SEK | 112.53% |
2023 Q4 | 14.01 Million SEK | 13.79% |
2023 Q2 | 42.6 Million SEK | 55.18% |
2023 Q3 | 12.31 Million SEK | -71.09% |
2023 Q1 | 27.45 Million SEK | 46.52% |
2023 FY | 14.01 Million SEK | -25.21% |
2022 Q2 | 45.05 Million SEK | 48.02% |
2022 Q4 | 18.74 Million SEK | 25.92% |
2022 FY | 18.74 Million SEK | -9.88% |
2022 Q1 | 30.44 Million SEK | 46.39% |
2022 Q3 | 14.88 Million SEK | -66.97% |
2021 Q2 | 12.01 Million SEK | 58.34% |
2021 Q3 | 8.92 Million SEK | -25.73% |
2021 Q4 | 20.79 Million SEK | 133.02% |
2021 FY | 20.79 Million SEK | -0.53% |
2021 Q1 | 7.58 Million SEK | -63.7% |
2020 Q2 | 28.32 Million SEK | 46.89% |
2020 FY | 20.9 Million SEK | 169.1% |
2020 Q4 | 20.9 Million SEK | 9.61% |
2020 Q3 | 19.07 Million SEK | -32.66% |
2020 Q1 | 19.28 Million SEK | 148.2% |
2019 Q1 | 3.91 Million SEK | -17.93% |
2019 FY | 7.76 Million SEK | 62.91% |
2019 Q3 | 4.18 Million SEK | -14.98% |
2019 Q4 | 7.76 Million SEK | 85.68% |
2019 Q2 | 4.92 Million SEK | 25.73% |
2018 Q3 | 18.37 Million SEK | 11.54% |
2018 FY | 4.76 Million SEK | -53.11% |
2018 Q4 | 4.76 Million SEK | -74.04% |
2018 Q1 | 11.39 Million SEK | 12.06% |
2018 Q2 | 16.47 Million SEK | 44.53% |
2017 Q4 | 10.17 Million SEK | 355.24% |
2017 FY | 10.17 Million SEK | 254.85% |
2017 Q1 | 1.71 Million SEK | -40.2% |
2017 Q2 | 2.21 Million SEK | 29.23% |
2017 Q3 | 2.23 Million SEK | 0.86% |
2016 FY | 2.86 Million SEK | -9.33% |
2016 Q4 | 2.86 Million SEK | 131.69% |
2016 Q3 | 1.23 Million SEK | -45.29% |
2016 Q2 | 2.26 Million SEK | 0.0% |
2016 Q1 | - SEK | -100.0% |
2015 FY | 3.16 Million SEK | 231.24% |
2015 Q4 | 3.16 Million SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2014 FY | 954.29 Thousand SEK | -52.34% |
2013 FY | 2 Million SEK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alligator Bioscience AB (publ) | 106.59 Million SEK | 86.852% |
Ziccum AB (publ) | 6.38 Million SEK | -119.396% |
Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -494.108% |
BioArctic AB (publ) | 139.5 Million SEK | 89.954% |
Sprint Bioscience AB (publ) | 34.6 Million SEK | 59.498% |
Mendus AB (publ) | 51.22 Million SEK | 72.64% |
Genovis AB (publ.) | 98.04 Million SEK | 85.706% |
Intervacc AB (publ) | 21.68 Million SEK | 35.355% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 47.525% |
Active Biotech AB (publ) | 13.4 Million SEK | -4.59% |
Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 88.696% |
Bio-Works Technologies AB (publ) | 16.11 Million SEK | 13.042% |
Aptahem AB (publ) | 8.99 Million SEK | -55.76% |
Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 65.699% |
Kancera AB (publ) | 17.97 Million SEK | 22.044% |
Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 69.651% |
Fluicell AB (publ) | 8.91 Million SEK | -57.207% |
Saniona AB (publ) | 86.08 Million SEK | 83.719% |
Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -171.714% |
Biovica International AB (publ) | 34.76 Million SEK | 59.689% |
Spago Nanomedical AB (publ) | 11.66 Million SEK | -20.115% |
AcouSort AB (publ) | 10.37 Million SEK | -35.045% |
Abliva AB (publ) | 16.78 Million SEK | 16.483% |
Egetis Therapeutics AB (publ) | 214.6 Million SEK | 93.469% |
Karolinska Development AB (publ) | 11.56 Million SEK | -21.143% |
OncoZenge AB (publ) | 1.69 Million SEK | -724.897% |
Amniotics AB (publ) | 10.54 Million SEK | -32.881% |
2cureX AB (publ) | 2.93 Million SEK | -377.513% |
CombiGene AB (publ) | 4.15 Million SEK | -237.223% |
Asarina Pharma AB (publ) | 4.42 Million SEK | -216.652% |
Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.105% |
Camurus AB (publ) | 414.81 Million SEK | 96.621% |
Corline Biomedical AB | 6.78 Million SEK | -106.437% |
IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 77.158% |
Isofol Medical AB (publ) | 19.16 Million SEK | 26.868% |
I-Tech AB | 16.2 Million SEK | 13.514% |
Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.818% |
Cyxone AB (publ) | 4.69 Million SEK | -198.573% |
ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -5.155% |
Biosergen AB | 5.08 Million SEK | -175.615% |
Cantargia AB (publ) | 54.97 Million SEK | 74.504% |
NextCell Pharma AB | 13.68 Million SEK | -2.381% |
Xspray Pharma AB (publ) | 71.85 Million SEK | 80.494% |
Elicera Therapeutics AB (publ) | 13.77 Million SEK | -1.768% |
Nanologica AB (publ) | 79.32 Million SEK | 82.333% |
SynAct Pharma AB | 51.83 Million SEK | 72.962% |
Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -76.311% |
Stayble Therapeutics AB (publ) | 5.19 Million SEK | -169.782% |
LIDDS AB (publ) | 3.75 Million SEK | -273.136% |
Lipum AB (publ) | 7.53 Million SEK | -85.925% |
BioInvent International AB (publ) | 90.45 Million SEK | 84.506% |
Alzinova AB (publ) | 9.33 Million SEK | -50.198% |
Oncopeptides AB (publ) | 181.59 Million SEK | 92.282% |
Pila Pharma AB (publ) | 1.79 Million SEK | -681.215% |
Guard Therapeutics International AB (publ) | 18.49 Million SEK | 24.219% |
Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -265.164% |
Simris Alg AB (publ) | 148.93 Million SEK | 90.59% |
Diamyd Medical AB (publ) | 71.11 Million SEK | 80.293% |
Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.093% |
Ascelia Pharma AB (publ) | 12.74 Million SEK | -9.973% |
Diagonal Bio AB (publ) | 7.26 Million SEK | -93.044% |